BASKING RIDGE, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR), a
commercial-stage bioelectronic medicine company, today announced the appointment of Ardelle Ferris to a new position within the
company, Vice President of Managed Care. Ardelle brings over 20 years of experience in national account management with PBMs and
commercial health plans. She joins electroCore after her most recent role as the Head of National Accounts at Intarcia
Therapeutics.
“Ardelle is a highly-anticipated, welcomed addition to our growing market access team, and her leadership will be critical to
shaping our PBM and commercial payer relationship strategies,” said Frank Amato, Chief Executive Officer of electroCore, “Her
specialized background and industry expertise in managed care combined with her collaborative spirit will be instrumental in
growing reimbursement coverage for gammaCore Sapphire in the United States.”
In her new role, Ardelle will be tasked with recruiting, training and leading electroCore’s field Market Access team, accountable
for achieving national sales goals set for several market segments, and contracting. Prior to her time with Intarcia Therapeutics,
Ardelle held National and Senior Account Manager positions at Pfizer and Vertex Pharmaceuticals for over 15 years. She holds a
Bachelor of Arts in Nursing degree from the University of Jamestown, and is a Registered Nurse.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform
non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and
rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and
product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in
nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of
similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding
needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore
operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and
electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as required by law. Investors should consult all of the
information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents
electroCore files with the SEC available at www.sec.gov.
Contacts
Investors:
Greg Chodaczek or Lynn Lewis
Gilmartin Group
investors@electrocore.com
(646) 924-1769
or
Media:
Alexandra Canale
GCI Health
(617) 921-9353
alexandra.canale@gcihealth.com
